The $50 million initiative aims to improve mental health treatments for veterans and others suffering from PTSD and depression
Category: Health
In a historic move, President Donald Trump signed an executive order on April 18, 2026, aimed at accelerating research and access to psychedelic drugs for mental health treatment, particularly for veterans suffering from post-traumatic stress disorder (PTSD) and other severe mental health conditions. The signing ceremony, held in the Oval Office, included notable figures such as Health and Human Services Secretary Robert F. Kennedy Jr., famous podcaster Joe Rogan, and military veterans like Marcus Luttrell.
Trump's executive order directs the U.S. Food and Drug Administration (FDA) to expedite the review process for psychedelic substances, including ibogaine, psilocybin, LSD, and MDMA. These drugs, often classified as Schedule I substances, have been largely illegal in the U.S. but are gaining attention for their potential therapeutic benefits. “Today’s order will dramatically accelerate access to new medical research and treatments based on psychedelic drugs,” Trump stated, emphasizing the need for effective alternatives to traditional mental health treatments.
The president announced a substantial investment of $50 million in federal funds to support research on ibogaine, a naturally occurring psychedelic that has shown promise in treating conditions like PTSD and traumatic brain injuries. “In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression—including our cherished veterans,” Trump noted.
During the event, Trump highlighted the tragic reality faced by veterans, stating, “Since 9/11, we've lost over 21 times more veteran lives to suicide than on the battlefield. Today, we're bringing them new hope.” His comments were echoed by Luttrell, who shared his personal experience with ibogaine treatment, saying, “It changed my life, and I look forward to seeing the impact it will have on countless others.”
The executive order aims to clear bureaucratic hurdles that have previously impeded research into these substances. It also includes provisions for improved data sharing between the FDA and the Department of Veterans Affairs (VA), which could facilitate faster rescheduling of any psychedelic drugs that gain FDA approval. Health Secretary Kennedy asserted, “We’re taking this decisive step to confront one of the most urgent public health challenges facing our nation, the mental health crisis.”
In addition to expediting the review process, the order opens a pathway for the use of ibogaine under the Right to Try law, allowing terminally ill patients access to this treatment. “We will support those efforts with funding, technical assistance, and data sharing consistent with applicable law,” Kennedy added.
Clinical trials have already indicated that psychedelics, particularly ibogaine, can effectively treat various mental health disorders. A 2024 study from Stanford University revealed that 30 special operations veterans treated with ibogaine experienced an 80% to 90% reduction in symptoms of depression and anxiety within just one month. “No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury,” study author Nolan Williams noted.
Trump's executive order comes on the heels of previous initiatives aimed at reforming drug policies, including his December 2025 order to research marijuana and cannabidiol. Critics of the accelerated approval process, including some mental health advocates, caution that it could compromise safety and oversight. They stress the importance of rigorous clinical trials before widespread use of these substances.
Nevertheless, the potential benefits of psychedelics have drawn bipartisan support. Lawmakers from various states are already pursuing legislation to support clinical trials aimed at developing ibogaine into a legal medication with FDA approval. Texas, for example, recently announced plans to initiate its own research program on ibogaine.
At the signing ceremony, Dr. Mehmet Oz, Administrator for the Centers for Medicare & Medicaid Services, remarked, “This is an entire paradigmatic shift away from a one-day-a-pill model, which has failed so many.” He emphasized the need to study the mechanisms behind these substances to fully understand their therapeutic potential.
The order is seen as a monumental change in how the U.S. approaches psychedelic drugs, which have been stigmatized for decades. Joe Rogan, a prominent advocate for psychedelic therapy, pointed out that ibogaine has shown remarkable potential in helping individuals overcome opioid addiction. “These drugs are illegal not because they're harmful, but because of the 1970 Controlled Substances Act,” he stated.
As the Trump administration moves forward with this initiative, many are watching closely to see how it will impact mental health treatment in the U.S. The FDA has already granted Breakthrough Therapy designation to some psychedelics, indicating substantial promise for future therapies. Government-sanctioned treatments could begin as soon as this summer, pending FDA authorization.
In a nation grappling with a mental health crisis, the urgency of this initiative cannot be overstated. Over 14 million American adults are diagnosed with serious mental illnesses, and more than 6,000 veterans take their lives annually. As Trump stated, “We owe it to our warfighters and veterans to turn over every stone to alleviate the emotional and mental health blowback from their deployments.”
The executive order marks a potential turning point in the treatment of PTSD and other mental health conditions, offering hope to countless individuals who have long struggled with debilitating symptoms. As discussions continue around the safety and efficacy of these treatments, the focus remains on finding effective solutions for those in desperate need.
With the promise of new research and the possibility of expanded access to psychedelic therapies, the coming months will be a decisive period for the future of mental health treatment in America. Will this bold initiative pave the way for a new era in mental health care, or will it face obstacles that hinder its progress? , but the stakes are undeniably high.